Woke Pharmaceuticals

Woke Pharmaceuticals is an Australian drug development company focused on the research and commercialization of psychedelic-based therapies for mental health disorders. The company's lead programs include WP-001, a synthetic psilocybin formulation being evaluated for treatment-resistant depression, and WP-002, a lysergic acid diethylamide (LSD) candidate for anxiety and alcohol use disorder. Woke Pharmaceuticals collaborates with leading Australian research institutions to conduct clinical trials and advance its pipeline of rapid-acting, durable treatments. The company aims to address the significant unmet need in psychiatry by providing novel alternatives to traditional antidepressants and behavioral therapies. Its strategic focus includes leveraging Australia's favorable regulatory environment for psychedelic research and clinical development.